Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Public ClinicalTrials.gov record NCT03749018. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Nivolumab in Combination With DA-REPOCH Followed by Short Course Nivolumab Consolidation in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Study identification
- NCT ID
- NCT03749018
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- David Bond, MD
- Other
- Enrollment
- 30 participants
Conditions and interventions
Conditions
- Aggressive Non-Hodgkin Lymphoma
- Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
- Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma
- Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
- Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma
- Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
- Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
- High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
- High Grade B-Cell Lymphoma, Not Otherwise Specified
- Indolent Non-Hodgkin Lymphoma
- Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
- Transformed Non-Hodgkin Lymphoma
Interventions
- Cyclophosphamide Drug
- Doxorubicin Hydrochloride Drug
- Etoposide Drug
- Nivolumab Biological
- Prednisone Drug
- Rituximab Biological
- Vincristine Sulfate Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 1, 2019
- Primary completion
- Feb 1, 2026
- Completion
- Dec 30, 2026
- Last update posted
- Feb 5, 2026
2019 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03749018, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 5, 2026 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03749018 live on ClinicalTrials.gov.